Exam 1 Study Guide Flashcards

1
Q

Lecture 1 -Weil

  1. Cell Types in the CNS

Glial cells: Basic function and biology

A

Oligodendrocytes: Wrap axons in myelin

Ependymal cells: Line ventricles; Produce cerebrospinal fluid

Astrocytes:

  • Star shaped
  • Structural frame work
  • Participate in blood brain barrier
  • Regulate what substances from the blood reach neurons
  • Survey neurons
  • Regulate synaptic communication among neurons
  • Have both protective and damaging effects in injury and disease.

Miroglia:

  • Similar to Monocytes/macrophages
  • Differentiate upon activation
  • Long survival (over 6 months)
  • Friend of neurons:
  • Phagocytose apoptotic neurons
  • Secrete neuroprotective factors: BDNF, Neurotrophin 3, etc.
  • Resting microglia secrete IL10
  • Foe of neurons
  • Secrete neurotoxic molecules: *TNF, IL1, glutamate, free radical species, etc.
  • Can induce apoptosis
  • Interact with astrocytes
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Activated vs. resting Microglia

A

Under normal physiological conditions, microglia in the CNS exist in the ramified or ‘resting’ state. Resting microglial cell are characterized by small cell bodies and thin processes, which send multiple branches and extend in all directions. Similar to astrocytes, every microglial cell has its own territory; there is very little overlap between neighboring territories. The processes of resting microglial cells are constantly moving through its territory; this is a relatively rapid movement, and thus microglial processes represent the fastest moving structures in the brain. At the same time, microglial processes also constantly send out and retract small protrusions, which can grow and shrink. The microglia seem to be scanning through their domains. These processes rest for periods of minutes at sites of synaptic contacts. Focal neuronal damage induces a rapid and concerted movement of many microglial processes towards the site of lesion, and the lesion gets completely surrounded by these processes. This is injury-induced motility. It appears that astrocytes signal to the microglia by releasing ATP (and possibly some other molecules). Microglial processes act as a very sophisticated and fast scanning system. This system can, by virtue of receptors residing in the microglial cell, immediately detect injury and initiate the process of active response, which eventually triggers the full blown microglial activation.

Activation of microglia:
Microglia constantly monitor the environment. Change in pH, osmolarity, extracellular ATP, heat shock proteins, cytokines, chemokines, bacterial components, viral components, cellular debris can cause microglia become activated

When a brain insult is detected by microglial cells, they launch a specific program that results in the gradual transformation of resting, ramified microglia into an ameboid form; this process is generally referred to as ‘microglial activation’ and proceeds through several steps. During the first stage of microglial activation resting microglia retract their processes, which become fewer and much thicker, increase the size of their cell bodies, change the expression of various enzymes and receptors, and begin to produce immune response molecules. Some microglial cells return into a proliferative mode, and microglial numbers around the lesion site start to multiply. Microglial cells become motile, and using amoeboid-like movements they gather around sites of insult. If the damage persists and CNS cells begin to die, microglial cells undergo further transformation and become phagocytes. This is, naturally, a rather sketchy account of the complex and highly coordinated changes which occur in microglial cells; the process of activation is gradual and most likely many sub-states exist on the way from resting to phagocytic microglia. Activated microglial cells may display heterogeneous properties in different pathologies and in different parts of the brain.

The ‘off-signals’ that may indicate deterioration in neural networks are not yet fully characterized. A good example for this type of communication is neurotransmitters. Microglial cells express a variety of the classical neurotransmitter receptors such as receptors for GABA, glutamate, dopamine, noradreanline. In most cases, activation of the receptors counteracts the activation of microglial cells with respect to acquiring a pro-inflammatory phenotype. Maybe the depression of neuronal activity could affect neighboring microglia, turning them into an ‘alerted’ state. In fact, these ‘off-signals’ allow microglia to sense disturbance even if the nature of the damaging factor cannot be identified.

The ‘on-signalling’ is conveyed by a wide array of molecules, either associated with cell damage or with foreign matter invading the brain. In particular, damaged neurons can release high amounts of ATP, cytokines, neuropeptides, and growth factors. Many of these factors can be sensed by microglia and trigger activation. It might be that different molecules can activate various subprogrammes of this routine, regulating therefore the speed and degree of microglial activation. Some of these molecules can carry both ‘off’ and ‘on’ signals: for example low concentrations of ATP may be indicative of normal on-going synaptic activity, whereas high concentrations signal cell damage. Microglia are also capable of sensing disturbances in brain metabolism: for example, accumulation of ammonia, which follows grave metabolic failures (e.g. during hepatic encephalopathy) can activate microglial cells either directly or via intermediates such as NO or ATP.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Glial cells Role in injury

A

??

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

glial “scar”

A

??
Astrocytes and microglia form “glial scar.”

Ablation of glial scar formation allows axons to grow through site of injury.
Unfortunately it also causes massive loss of neurons.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Cell Types Involved in Inflammation

A

???

monocytes, macrophages, lymphocytes, plasma cells, fibroblasts

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Damaging vs. beneficial effects

of Inflammation

A

In some cases anti-inflammatory treatments are effective, in many cases not.

Inflammation has been implicated in depression,
Alzheimer’s, stroke, TBI, spinal cord injury, Parkinson’s, retinal degeneration, ALS, etc. etc.

Beneficial effects:

Dilution of toxins: produced by bacteria, are carried away.

Entry of Antibodies: Increased vascular permeability allows antibodies to enter the extravascular space, where they may lead either to Iysis of microorganisms, or to their phagocytosis. Antibodies are also important in neutralization of toxins.

Drug Transport: The fluid carries with it therapeutic drugs such as antibiotics to the site where bacteria are multiplying.

Fibrin Formation: Fibrin formation from exuded fibrinogen may impede the movement of micro-organisms, trapping them and facilitating phagocytosis.

Delivery of Oxygen & Nutrients: Delivery of nutrients and oxygen, essential for cells such as neutrophils which have high metabolic activity, is aided by increased fluid flow through the area.

Stimulation of immune response: The drainage of this fluid exudate into the lymphatics allows particulate and soluble antigens to reach the local Iymph nodes where they may stimulate the immune response.

Harmful Effects:

Digestion of Normal Tissues: Enzymes such as collagenases and proteases may digest normal tissues, resulting in their destruction. This may result particularly in vascular damage.

Swelling - The swelling of acutely inflamed tissues may be harmful. Inflammatory swelling is especially serious when it occurs in an enclosed space such as the cranial cavity. Thus, acute meningitis or a cerebral abscess may raise intracranial pressure to the point where blood flow into the brain is impaired.

Inappropriate Inflammatory Response: Sometimes, acute inflammatory responses appear inappropriate, such as those which occur in type I hypersensitivity reactions (e.g. hay fever) where the provoking environmental antigen (e.g. pollen) otherwise poses no threat to the individual. Such allergic inflammatory responses may be life-threatening, for example extrinsic asthma.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Definition of Excitotoxicity

A

exaggerated and continuous stimulation by a neurotransmitter, especially in those neuronal systems which use glutamate as the transmitter.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Excitotoxicity:

When does it happen?

A

Cell Death is associated with excessive calcium entry
through NMDA receptors.

Localized increases in [Ca2+]i
trigger physiological events

Excessive Ca2+ loading activates processes that lead to cell death

Neurotoxicity mediated by glutamate receptors is largely calcium dependent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Excitotoxicity:

Calcium

A

NMDA receptors allows the passage of both Na+ and Ca++ ions. They are more permeable to Ca++

Cell Death is associated with excessive calcium entry
through NMDA receptors

Localized increases in [Ca2+]i
trigger physiological events

Excessive Ca2+ loading activates processes that lead
to cell death

Neurotoxicity mediated by glutamate receptors is largely calcium dependent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Types of glutamate receptors

A

Ionotropic Glutamate Receptors:

AMPA and Kainate receptors generally allow the passage of
Na+ and K+

NMDA receptors allows the passage of both Na+ and Ca++ ions. More permeable to Ca++

AMPA receptors:
Mediate most fast EPSPs in the CNS

Kainate receptors:
Regulation of neuronal excitability, epilepsy, excitotoxicity, and pain

NMDA receptors mediate most fast EPSPs in the CNS 
§ Anaesthesia
§ Learning and memory 
§ Developmental plasticity 
§ Epilepsy 
§ Excitotoxicity (eg stroke) 
§ Schizophrenia 

Glutamate activates 2 types of ion channels (AMPA and NMDA)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

NMDA receptor

A

A subtype of glutamate receptor; a glutamate-gated ion channel that is permeable to Na+, K+, and Ca2+. Inward ionic current through the
N-methyl-D-aspartate receptor is voltage dependent because of a magnesium block at negative membrane potentials.

The NMDA receptor is distinct in 2 ways:
First, it is both ligand-gated and voltage-dependent.
Second, it requires co-activation by two ligands: glutamate and either D-serine or glycine.

The N-methyl-D-aspartate receptor (aka, the NMDA receptor or NMDAR) is the predominant molecular device for controlling synaptic plasticity and memory function.

The NMDAR is a specific type of ionotropic glutamate receptor. NMDA (N-methyl-D-aspartate) is the name of a selective agonist that binds to NMDA receptors, but not to other glutamate receptors.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

NMDA vs. non-NMDA

A

non-NMDA:
AMPA & KAINATE, both are Ligand-gated ion channels

NMDA (N-methyl-D-aspartate) is the name of a selective agonist that binds to NMDA receptors, but not to other glutamate receptors (ie, not to AMPA or Kainate).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Definition of Oxidative Stress

A

An excess of free-radicals damages cells and is called oxidative stress.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

AMPA receptor

A

A subtype of glutamate receptor; a glutamate-gated ion channel that is permeable to
Na+ and K+.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

kainate receptor

A

A subtype of glutamate receptor; a glutamate-gated ion channel that is permeable to Na+ and K+.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Why is the brain vulnerable to excitotoxicity?

A

It contains more fatty acids.

It has few antioxidants.

It has high oxygen consumption.

It has high levels of iron and ascorbate (worse oxidative stress).

Dopamine and glutamine oxidation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Evidence that schizophrenia is a neurodevelopmental disorder:

A

Ø MANY RISK FACTOR GENES ARE ASSOCIATED WITH
DEVELOPMENT OF THE NERVOUS SYSTEM

Ø NEURONAL MIGRATION ERRORS IN NEOCORTEX AND
HIPPOCAMPUS

Ø DISRUPTION OF EXCITATORY/INHIBITORY BALANCE

Ø OBSTETRIC COMPLICATIONS AND IMMUNE CHALLENGES DURING PREGNANCY INCREASE RISK

Ø ADOLESCENCE AS A RISK FACTOR FOR SYMPTOM
ONSET

Ø NEURODEVELOPMENTAL ANIMAL MODELS RECREATE
ASPECTS OF THE SCHIZOPHRENIC PHENOTYPE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Positive Symptoms of Schizophrenia

A

hallucinations; delusions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Negative Symptoms of Schizophrenia

A

avolition; ambivalent affect

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Dysregulation of cholinergic and glutamatergic systems

A

Antagonists tend to be psychotomimetics

Reduced acetylcholine and glutamate receptors in Schizophrenic patients

Kyenurinine pathway

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

____ receptor ___ are psychotomimetic

A

NMDA receptor antagonists are psychotomimetic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

There is reduced expression of nAChR and NMDAR mRNA in

patients with Schizophrenia

A

Reduced acetylcholine and glutamate receptors in Schizophrenia patients

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Kynurenine pathway:

Cell Types Involved

A

Astrocyte, Neurons

Microglia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Kynurenine pathway:

Pharmacological effects of kynurenic acid

A

Acute elevations of brain KYNA in adults produced SZ-like cognitive deficits (working memory)

Chronic elevations during early development resulted in dysregulations in cortical-subcortical interactions

The mesolimbic modulation of prefrontal glutamate release was markedly weakened;
cortical excitation may be further compromised via loss of dendritic spines

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Kynurenine pathway

Effects of acute and developmental elevation of kynurenenic acid

A

ELEVATIONS IN BRAIN KYNA DURING EARLY DEVELOPMENT DISRUPT THE MATURATION OF EXCITATORY/INHIBITORY BALANCE WITHIN THE PFC

Acute elevations of brain KYNA in adults produced SZ-like cognitive deficits

ELEVATIONS OF BRAIN KYNURENIC ACID DURING DEVELOPMENT LEAD TO A REDUCTION IN CORTICAL DENDRITIC SPINES

EKYNs EXHIBIT JUVENILE-LIKE LOSS OF GABAergic TONE IN PFC

26
Q

Differences between unipolar and bipolar depression

A

When you hear people talk about being diagnosed with or treated for depression, they are often referring to unipolar depression.

There are differences between unipolar depression and bipolar depression in how the illness makes people feel and behave, and differences in how they are supported through treatment.

In addition to going through low moods or depression, individuals with bipolar disorder also have high moods (mania) during which they may experience increased energy, feelings of euphoria, insomnia (inability to sleep) or impulsive behaviors like shopping sprees or promiscuous sex.

Someone with unipolar depression doesn’t go through the “highs” of bipolar depression.

27
Q

Course and history

A

Big industry, big money

28
Q

Evidence in favor of monoamine hypothesis

Role of MAO, SERT, NET, DAT, vMAT

A

??

MAO

29
Q

MAO

A

L-Monoamine oxidases (MAO) are a family of enzymes that catalyze the oxidation of monoamines. They are found bound to the outer membrane of mitochondria in most cell types in the body.

In humans there are two types of MAO: MAO-A and MAO-B. Both are found in neurons and astroglia.

Both MAOs are also vital to the inactivation of monoaminergic neurotransmitters, for which they display different specificities.

Serotonin, melatonin, noradrenaline, and adrenaline are mainly broken down by MAO-A.

Phenethylamine and benzylamine are mainly broken down by MAO-B.

Both forms break down dopamine, tyramine, and tryptamine equally.

Because of the vital role that MAOs play in the inactivation of neurotransmitters, MAO dysfunction (too much or too little MAO) is thought to be responsible for a number of neurological disorders. Uunusually high or low levels of MAOs in the body have been associated with schizophrenia, depression, ADD, substance abuse, migraines, etc. Monoamine oxidase inhibitors are one of the major classes of drug prescribed for the treatment of depression, although they are often last-line treatment due to risk of the drug’s interaction with diet or other drugs. Excessive levels of catecholamines (epinephrine, norepinephrine, and dopamine) may lead to a hypertensive crisis, and excessive levels of serotonin may lead to serotonin syndrome.

MAO-A inhibitors act as antidepressant and antianxiety agents, whereas MAO-B inhibitors are used alone or in combination to treat Alzheimer’s and Parkinson’s diseases.

MAO is also heavily depleted by use of tobacco cigarettes.

Animal Models:
Mice unable to produce either MAO-A or MAO-B display autistic-like traits. These knockout mice display an increased response to stress.

30
Q

SERT

A

The serotonin transporter (SERT or 5-HTT) is a type of monoamine transporter protein that transports serotonin from the synaptic cleft to the presynaptic neuron.

This transport of serotonin by the SERT protein terminates the action of serotonin and recycles it in a sodium-dependent manner. This protein is the target of many antidepressant medications, including those of the SSRI class. It is a member of the sodium:neurotransmitter symporter family. A repeat length polymorphism in the promoter of this gene has been shown to affect the rate of serotonin uptake and may play a role in sudden infant death syndrome, aggressive behavior in Alzheimer disease patients, post-traumatic stress disorder and depression-susceptibility in people experiencing emotional trauma.

The serotonin transporter removes serotonin from the synaptic cleft back into the synaptic boutons. Thus, it terminates the effects of serotonin and simultaneously enables its reuse by the presynaptic neuron.

Neurons communicate by using chemical messengers like serotonin between cells. The transporter protein, by recycling serotonin, regulates its concentration in a gap, or synapse, and thus its effects on a receiving neuron’s receptors.

Changes in serotonin transporter metabolism appear to be associated with many different phenomena, including alcoholism, clinical depression, obsessive-compulsive disorder (OCD), romantic love, hypertension and generalized social phobia.

The serotonin transporter is also present in platelets; there, serotonin functions as a vasoconstrictive substance.

SERT belongs to the NE, DA, SERT monoamine transporter family. Transporters are important sites for agents that treat psychiatric disorders. Drugs that reduce the binding of serotonin to transporters (selective serotonin reuptake inhibitors, SSRIs) are used to treat mental disorders. About half of patients with OCD are treated with SSRIs. Fluoxetine is an example of a selective serotonin reuptake inhibitor.

31
Q

Axon terminals (also called synaptic boutons)

A

The presynaptic terminal, or synaptic bouton, is a specialized area within the axon of the presynaptic cell that contains neurotransmitters enclosed in small membrane-bound synaptic vesicles (as well as in other supporting structures and organelles, such as mitochondria and endoplasmic reticulum). Synaptic vesicles are docked at the presynaptic plasma membrane at regions called active zones.

32
Q

NET

A

The norepinephrine transporter (NET), also known as solute carrier family 6 member 2 (SLC6A2), is a protein in humans.

NET is a monoamine transporter and is responsible for the sodium-chloride (Na+/Cl–)-dependent reuptake of extracellular norepinephrine (NE; aka, noradrenaline).

NET can also reuptake extracellular dopamine (DA). The reuptake of these 2 neurotransmitters is essential in regulating concentrations in the synaptic cleft. NETs, along with the other monoamine transporters, are the targets of many antidepressants and recreational drugs. An over abundance of NET is associated with ADHD. There is evidence that single-nucleotide polymorphisms in the NET gene may be an underlying factor in some of these disorders.

Certain antidepressant medications act to raise noradrenaline, such as serotonin-norepinephrine reuptake inhibitors (SNRIs), norepinephrine-dopamine reuptake inhibitors (NDRIs), norepinephrine reuptake inhibitors (NRIs or NERIs) and the tricyclic antidepressants (TCAs). The mechanism is that the reuptake inhibitors prevent the reuptake of serotonin and norepinephrine by the presynaptic neuron, paralyzing the normal function of the NET. At the same time, higher levels of 5-HT are maintained in the synapse, increasing the concentrations of the serotonin and norepinephrine. Since the noradrenaline transporter is responsible for most of the dopamine clearance in the prefrontal cortex, SNRIs block reuptake of dopamine too, accumulating the dopamine in the synapse. However, DAT, the primary way dopamine is transported out of the cell, can work to decrease dopamine concentration in the synapse when the NET is blocked. For many years, the number one choice in treating mood disorders like depression was through the uptake of TCAs. However, currently far more potent drugs have been developed in the US, most notably the discovery of selective serotonin reuptake inhibitors (SSRIs). SSRIs affect the communication between chemical messengers in the brain by regulating how much of a certain chemical messenger enters the brain. SSRIs regulate serotonin levels in the brain, which seems to aid the brain in exchanging messages more efficiently and in turn livens mood. Drugs such as fluoxetine and paroxetine are both very impelling in treating mood disorders because they reduce many of the side effects one receives compared to using TCAs to treat such mood disorders.

33
Q

DAT

A

The dopamine transporter (aka, dopamine active transporter, DAT) is a membrane-spanning protein that pumps the neurotransmitter dopamine out of the synapse back into cytosol, from which other transporters sequester DA and NE into vesicles for later storage and release. Dopamine reuptake via DAT provides the primary mechanism through which dopamine is cleared from synapses, although there may be an exception in the prefrontal cortex, where norepinephrine transporter takes a possibly larger role.

DAT is implicated in a number of dopamine-related disorders, including attention deficit hyperactivity disorder, bipolar disorder, clinical depression, and alcoholism. Evidence for the associations between DAT and dopamine related disorders has come from a genetic polymorphism.

DAT is an integral membrane protein that removes dopamine from the synaptic cleft and deposits it into surrounding cells, thus terminating the signal of the neurotransmitter. Dopamine underlies several aspects of cognition, including reward, and DAT facilitates regulation of that signal.

34
Q

vMAT

A

The vesicular monoamine transporter (VMAT) is a transport protein integrated into the membrane of synaptic vesicles of presynaptic neurons. It acts to transport monoamine neurotransmitters - such as dopamine, serotonin, norepinephrine, epinephrine, and histamine - into the vesicles, which release the neurotransmitters into synapses as chemical messages to postsynaptic neurons. VMATs utilize a proton gradient generated by V-ATPases in vesicle membranes to power monoamine import.

Monoamines transported by VMATs are mainly noradrenaline, adrenaline, dopamine, serotonin, histamine, and trace amines.

Pharmaceutical drugs that target VMATs have possible applications for many conditions, including drug addiction, psychiatric disorders, Parkinson’s disease, etc. Many drugs that target VMAT act as inhibitors and alter the kinetics of the protein.

Studies using a genetic rodent model to understand depression in humans suggest that VMAT2 genetic or functional alterations play a role in depression. Reduced VMAT2 levels were identified in specific regions of the striatum involved in depression, including the nucleus accumbens, the ventral tegmental area, and the substantia nigra. The reduced VMAT2 protein levels were not accompanied by similar levels of VMAT2 mRNA alterations. It has been proposed that VMAT2 activity is not altered at the level of genetic expression, but may rather be altered at the functional level in ways that may correlate with depression.

35
Q

Historical drugs

A

Reserpine (early antihypertensive) inhibits vMATs which load neruotransmitters. People who took this fell into intense depression.

Iproniazid (mediocre antidepressant used to treat TB)

Imipramine (originally studied as an antipsychotic). MAO inhibitor. Don’t eat cheese because cheese contains too much tryptophan which increases serotonin! Imipramine is an antidepressant that inhibits MAO, so the MAO can’t break down the serotonin as quickly, and hence, too much serotonin is left in the synapse for too long.

Drugs enhancing noradrenergic functioning were antidepressants (eg. stimulants)

36
Q

5HT (seritonin) is broken down by MAO to 5-HIAA

A

??

37
Q

Norepinephrine System in depressed patients

A

Seems hyperactive. But since there are fewer noradrenergic neurons, this can lead to a deficiency.

Adverse childhood experiences can produce an over-active responsiveness in this system that persists into adulthood.

In situations that most people may not find too stressful, the vulnerable depressed individual does feels very stressed and may deplete NE. Depletion of NE with AMPT causes depression in recovered patients but not normals.

Restraint stress in animals causes NE depletion and hopelessness. Hopelessness is part of major depression.

38
Q

Dopamine Function is Deficient in Major Depression

A

Parkinson’s Disease associated with depression.

CSF shows low homovanillic acid (HVA).

Neuroendocrine challenges: blunted responses to dopamine agonists

Depletion of dopamine with AMPT causes depression in recovered patients but not
normals.

Imaging: nothing found yet.

Postmortem brain: no data

Genes: TH, COMT & MAO

39
Q

Why is serotonin pharmacology complicated?

A

??

40
Q

Platelets Used as a Serotonin Neuron Model In Studies of Major Depression

A

Lots of serotonin-related abnormalities.

Serotonin uptake low.

Serotonin transporter sites are fewer.

More 5-HT2A receptors in association with suicidal acts.

5-HT2A signal transduction is blunted in suicidal cases.

Possible link to increased risk of death from myocardial infarction in major depression.

41
Q

Serotonin 5-HT1A Receptors

A

Major part of serotonin communication in brain.

Both an autoreceptor and a terminal field post-synaptic receptor.

42
Q

autoreceptor

A

A receptor in the membrane of a presynaptic axon terminal that is sensitive to the neurotransmitter released by that terminal.

Maintains homeostasis

43
Q

5-HT

A

serotonin

An amine neurotransmitter,
5-hydroxytryptamine.

44
Q

monoamine hypothesis of mood disorders

A

A hypothesis suggesting that depression is a consequence of a reduction in the levels of monoamine neurotransmitters, particularly serotonin and norepinephrine, in the brain.

45
Q

antidepressant drug

A

A drug that treats the symptoms
of depression by elevating brain levels of monoamine neurotransmitters; examples are tricyclics, monoamine oxidase (MAO) inhibitors, and SSRIs.

46
Q

Endocrine changes in major depression:

Dexamethasone suppression test

A

??

47
Q

Endocrine changes in major depression:

Changes in hippocampal morphology and neurogenesis

A

??

48
Q

Endocrine changes in major depression:

Different changes in the amygdala

A

??

49
Q

Endocrine changes in major depression:

Role of the hippocampus in negative feedback

A

??

50
Q

Endocrine changes in major depression:

Evidence of neurogenesis necessary for antidepressant effects

A

??

51
Q

Inflammation and depression:

Evidence for macrophage/cytokine theory

A

??

52
Q

Inflammation and depression:

Similarity between sickness and depression?

A

??

53
Q

Epigenetic studies:

Cross fostering study

A

??

54
Q

Epigenetic studies:

Changes in stress responses (GR)

A

??

55
Q

Difference between illness and disease relation to biomedical model

A

Biomedical model:

  • -Illness is explained by a discernible biophysical process (i.e., pathology)
  • -Disease causes illness
  • -Health is dichotomous (sick vs. well)

Illness judged to be caused by disease

    • Legitimate
    • Non-voluntary
    • Patient “not responsible”
56
Q

Functional somatic symptoms

A

Refers to a change in function rather than structure

Reifies the symptom, but sidesteps issue of causality

57
Q

Medically Unexplained Symptoms (MUS)

A

Deceptively neutral term

Risks implying that symptoms are outside the realm of
medical experience and that the problem is “undiagnosable” (“The doctors don’t know what’s wrong!”)

58
Q

Functional somatic symptoms:

Relationship to psychiatric symptoms?

A

????

“Comorbid” somatic and psychiatric symptoms
and disorders

Predict future somatic and psychiatric symptoms
and disorders

Mental/psychiatric disorder
“Real”, mental, and medically unexplained
– Non-intentional, non-voluntary
– Somatoform (DSM IV)/Somatic Symptom (DSM5) disorders
– “Emotional” disorders (Anxiety and/or Mood Disorders)

Association with anxiety and depression
– ↑ levels of MUS associated with ↑ emotional sx

59
Q

Threat appraisal

A

§ Threat sensitivity
§ Temperamental antecedents
§ Neuroticism, negative affect, harm avoidance
§ Response to life challenge at lower thresholds
§ Acoustic startle, visceral hypersensitivity, immune activation

Similar response to coping strategies
§ Passive coping
§ Avoid confronting pain (avoidance, wishful thinking)
§ ↑ levels anxiety/depression/pain
§ Accomodative coping
§ Accept and adjust to pain/distress
§ ↓ levels anxiety/depression/pain
§ Active coping
§ Problem focused to make pain “go away”
§ ↓ levels anxiety/depression but +/- pain

Fear 
§ Brain state(s) associated with perception of 
punishment/threat 
§ Neural system to detect and respond to danger 
§ Importance of the Amygdala
§ Central to fear circuitry 
§ Medial temporal lobe structure 
§ Almond shaped
60
Q

Dexamethasone suppression test

A

This test is done when the doctor suspects that your body is producing too much cortisol. It is done to help diagnose Cushing syndrome and identify the cause.

The low-dose test can help tell whether your body is producing too much ACTH. The high-dose test can help determine whether the problem is in the pituitary gland (Cushing disease).

Dexamethasone is a man-made (synthetic) steroid that is similar to cortisol. It reduces ACTH release in normal people. Therefore, taking dexamethasone should reduce ACTH level and lead to a decreased cortisol level.

If your pituitary gland produces too much ACTH, you will have an abnormal response to the low-dose test. But you can have a normal response to the high-dose test.

Dexamethasone suppression test measures whether adrenocorticotrophic hormone (ACTH) secretion by the pituitary can be suppressed.

Neuroendocrine abnormalities present in depressive illness and use of the dexamethasone suppression test (DST) in diagnosing depression are reviewed. The coexistence of neuroendocrine disturbances and depressive illness may be explained by a central nervous system neurochemical abnormality. Norepinephrine appears to inhibit hypothalamic corticotropin-releasing factor, thus decreasing ACTH secretion by the pituitary and, in turn, cortisol secretion by the adrenal glands. Thus, a deficiency in brain norepinephrine may lead to both depressive symptoms and increased adrenal cortisol production. Episodes of cortisol secretion are longer and more frequent in depressed patients, and the circadian rhythm of cortisol release is altered. Dexamethasone does not suppress plasma cortisol levels in depressed patients as compared with normal subjects. Abnormal DST results were obtained in 40-70% of inpatients and 20-50% of outpatients diagnosed as having unipolar primary depression or major depressive illness. The incidence of abnormal DST results in most nondepressed psychiatric patients is comparable with that in normal subjects. DST results do not distinguish between unipolar and bipolar depression but may differentiate primary from secondary depression. Depressed patients with abnormal DSTs responded positively to drug treatment. DST nonsuppressors responded more favorably to norepinephrine-reuptake blockers, while DST suppressors preferentially improved with serotonin-reuptake blockers. Normalization of DST response has been associated with clinical improvement. Certain drugs, a number of psychiatric conditions, and several major physical illnesses may alter DST response. The DST is a commonly used and practical tool in evaluating depressive illness; however, its diagnostic value in depressed outpatients and elderly depressed patients is not clear.

61
Q

Role of the hippocampus in negative feedback

A

Cortisol produced in the adrenal cortex will negatively feedback to inhibit both the hypothalamus and the pituitary gland.